Table of Contents Author Guidelines Submit a Manuscript
Advances in Preventive Medicine
Volume 2011 (2011), Article ID 597163, 7 pages
http://dx.doi.org/10.4061/2011/597163
Research Article

Effectiveness of Ezetimibe in Reducing the Estimated Risk for Fatal Cardiovascular Events in Hypercholesterolaemic Patients with Inadequate Lipid Control While on Statin Monotherapy as Measured by the SCORE Model

1Departments of Surgery and Epidemiology & Biostatistics, McGill University, Montreal, QC, Canada
2JSS Medical Research Inc., 4492 St., Catherine Street West, Westmount, QC, Canada H3Z 1R7
3Merck & Co, 16711 Trans Canada Highway, Kirkland, QC, Canada

Received 22 June 2010; Accepted 13 October 2010

Academic Editor: John Iskander

Copyright © 2011 John S. Sampalis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Statistics Canada. CANSIM, http://cansim2.statcan.ca/.
  2. M. Evans, A. Roberts, and A. Rees, “Pharmacological management of hyperlipidaemia,” British Journal of Diabetes and Vascular Disease, vol. 3, no. 3, pp. 204–210, 2003. View at Google Scholar · View at Scopus
  3. S. M. Grundy, J. I. Cleeman, C. N. Merz et al., “Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines,” Journal of the American College of Cardiology, vol. 44, no. 3, pp. 720–732, 2004. View at Google Scholar · View at Scopus
  4. P. H. Jones, “Lower is better: LDL-C goal achievement and statin efficacy in coronary prevention,” Medscape Cardiology, vol. 8, no. 1, 2004. View at Google Scholar
  5. C Baigent, A. Keech, P. M. Kearney et al., “Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins,” The Lancet, vol. 366, pp. 1267–1278, 2005. View at Google Scholar
  6. H.-W. Hense, H. Schulte, H. Löwel, G. Assmann, and U. Keil, “Framingham risk function overestimates risk of coronary heart disease in men and women from Germany—results from the MONICA Augsburg and the PROCAM cohorts,” European Heart Journal, vol. 24, no. 10, pp. 937–945, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. R. M. Conroy, K. Pyörälä, A. P. Fitzgerald et al., “Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project,” European Heart Journal, vol. 24, no. 11, pp. 987–1003, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Genest, J. Frohlich, G. Fodor, and R. McPherson, “Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update,” CMAJ, vol. 169, no. 9, pp. 921–924, 2003. View at Google Scholar · View at Scopus
  9. J. Genest, R. McPherson, J. Frohlich et al., “2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult—2009 recommendations,” Canadian Journal of Cardiology, vol. 25, no. 10, pp. 567–579, 2009. View at Google Scholar · View at Scopus
  10. C. Bourgault, J. Davignon, G. Fodor et al., “Statin therapy in Canadian patients with hypercholesterolemia: the Canadian lipid study—observational (CALIPSO),” Canadian Journal of Cardiology, vol. 21, no. 13, pp. 1187–1193, 2005. View at Google Scholar · View at Scopus
  11. K. A. Foley, R. J. Simpson Jr., J. R. Crouse III, T. W. Weiss, L. E. Markson, and C. M. Alexander, “Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events,” American Journal of Cardiology, vol. 92, no. 1, pp. 79–81, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. T. A. Pearson, I. Laurora, H. Chu, and S. Kafonek, “The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals,” Archives of Internal Medicine, vol. 160, no. 4, pp. 459–467, 2000. View at Google Scholar · View at Scopus
  13. R. H. Knopp, H. Gitter, T. Truitt et al., “Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia,” European Heart Journal, vol. 24, no. 8, pp. 729–741, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. S. E. Conard, H. E. Bays, L. A. Leiter et al., “Efficacy and Safety of Ezetimibe Added on to Atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease conflicts of interest,” American Journal of Cardiology, vol. 102, no. 11, pp. 1489–1494, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. L. A. Leiter, H. Bays, S. Conard et al., “Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease,” American Journal of Cardiology, vol. 102, no. 11, pp. 1495–1501, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. H. W. O. Roeters van Lennep, H. L. An, P. H. J. M. Dunselman, G. M. Dallinga-Thie, A. H. Zwinderman, and J. W. Jukema, “The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study,” Current Medical Research and Opinion, vol. 24, no. 3, pp. 685–694, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Farnier, M. Averna, L. Missault et al., “Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy—the IN-CROSS study,” International Journal of Clinical Practice, vol. 63, no. 4, pp. 547–559, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Feldman, M. Koren, W. Insull Jr. et al., “Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III Low-Density lipoprotein cholesterol goals,” American Journal of Cardiology, vol. 93, no. 12, pp. 1481–1486, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. E. Stein, S. Stender, P. Mata et al., “Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin,” American Heart Journal, vol. 148, no. 3, pp. 447–455, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. M. A. Ostad, S. Eggeling, P. Tschentscher et al., “Flow-mediated dilation in patients with coronary artery disease is enhanced by high dose atorvastatin compared to combined low dose atorvastatin and ezetimibe: results of the CEZAR study,” Atherosclerosis, vol. 205, no. 1, pp. 227–232, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Hedenmalm, G. Alvan, P. Öhagen, and M.-L. Dahl, “Muscle toxicity with statinsy,” Pharmacoepidemiology and Drug Safety, vol. 19, no. 3, pp. 223–231, 2010. View at Publisher · View at Google Scholar
  22. M. H. Davidson and J. G. Robinson, “Safety of aggressive lipid management,” Journal of the American College of Cardiology, vol. 49, no. 17, pp. 1753–1762, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Bissonnette, R. Habib, F. Sampalis, S. Boukas, and J. S. Sampalis, “Efficacy and tolerability of ezetimibe 10 mg/day coadministered with statins in patients with primary hypercholesterolemia who do not achieve target LDL-C while on statin monotherapy: a Canadian, multicentre, prospective study—the Ezetrol add-on study,” Canadian Journal of Cardiology, vol. 22, no. 12, pp. 1035–1044, 2006. View at Google Scholar · View at Scopus
  24. T. Thom, N. Haase, W. Rosamond et al., “Heart disease and stroke statistics—2006 Update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee,” Circulation, vol. 113, no. 6, pp. e85–e151, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. D. P. Mikhailidis, G. C. Sibbring, C. M. Ballantyne, G. M. Davies, and A. L. Catapano, “Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy,” Current Medical Research and Opinion, vol. 23, no. 8, pp. 2009–2026, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. D. B. Araujo, M. C. Bertolami, W. P. Ferreira et al., “Pleiotropic effects with equivalent low-density lipoprotein cholesterol reduction: comparative study between simvastatin and simvastatin/ezetimibe coadministration,” Journal of Cardiovascular Pharmacology, vol. 55, no. 1, pp. 1–5, 2010. View at Publisher · View at Google Scholar
  27. M. Yamaoka-Tojo, T. Tojo, R. Kosugi et al., “Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia,” Lipids in Health and Disease, vol. 8, article 41, 2009. View at Google Scholar
  28. T. A. Pearson, C. M. Ballantyne, E. Veltri et al., “Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy,” American Journal of Cardiology, vol. 103, no. 3, pp. 369–374, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. P. J. Devine, M. A. Turco, and A. J. Taylor, “Design and rationale of the ARBITER 6 trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)-6-HDL and LDL Treatment Strategies in atherosclerosis (HALTS),” Cardiovascular Drugs and Therapy, vol. 21, no. 3, pp. 221–225, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. C. P. Cannon, R. P. Giugliano, M. A. Blazing et al., “Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes,” American Heart Journal, vol. 156, no. 5, pp. 826–832, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. C. Cooke, L. Nissen, I. Sketris, and S. E. Tett, “Quantifying the use of the statin antilipemic drugs: comparisons and contrasts between Nova Scotia, Canada, and Queensland, Australia,” Clinical Therapeutics, vol. 27, no. 4, pp. 497–508, 2005. View at Publisher · View at Google Scholar · View at Scopus